Gene Therapy Development Progress Sends Beam Therapeutics (BEAM.US) Shares Soaring

Stock News01-13

Beam Therapeutics (BEAM.US) shares surged more than 20% on Monday, closing up 22.29% at $33.69. This significant increase followed the company's announcement detailing its ongoing commitment to establishing a sustainable and predictable model for advancing precision genetic medicines. The company highlighted recent progress within its liver-targeted genetic diseases and hematology franchise programs, outlined its strategic priorities for 2026, and noted an extension of its anticipated cash runway. The company's cash, cash equivalents, and marketable securities were valued at approximately $1.25 billion as of the end of 2025. The expected cash runway has been extended into 2029, which is projected to provide substantial support for the anticipated launch of risto-cel and the execution of the BEAM-302 pivotal development program. Furthermore, the expansion of the company's liver-targeted genetic diseases franchise is actively underway.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1114112458?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-13 10:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114112458","market":"other","top_or_hot":-1,"title":"Gene Therapy Development Progress Sends Beam Therapeutics (BEAM.US) Shares Soaring","media":"Stock News","content":"<p>Beam Therapeutics (BEAM.US) shares surged more than 20% on Monday, closing up 22.29% at $33.69. This significant increase followed the company's announcement detailing its ongoing commitment to establishing a sustainable and predictable model for advancing precision genetic medicines. The company highlighted recent progress within its liver-targeted genetic diseases and hematology franchise programs, outlined its strategic priorities for 2026, and noted an extension of its anticipated cash runway. The company's cash, cash equivalents, and marketable securities were valued at approximately $1.25 billion as of the end of 2025. The expected cash runway has been extended into 2029, which is projected to provide substantial support for the anticipated launch of risto-cel and the execution of the BEAM-302 pivotal development program. Furthermore, the expansion of the company's liver-targeted genetic diseases franchise is actively underway.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Gene Therapy Development Progress Sends Beam Therapeutics (BEAM.US) Shares Soaring</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGene Therapy Development Progress Sends Beam Therapeutics (BEAM.US) Shares Soaring\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-13 10:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Beam Therapeutics (BEAM.US) shares surged more than 20% on Monday, closing up 22.29% at $33.69. This significant increase followed the company's announcement detailing its ongoing commitment to establishing a sustainable and predictable model for advancing precision genetic medicines. The company highlighted recent progress within its liver-targeted genetic diseases and hematology franchise programs, outlined its strategic priorities for 2026, and noted an extension of its anticipated cash runway. The company's cash, cash equivalents, and marketable securities were valued at approximately $1.25 billion as of the end of 2025. The expected cash runway has been extended into 2029, which is projected to provide substantial support for the anticipated launch of risto-cel and the execution of the BEAM-302 pivotal development program. Furthermore, the expansion of the company's liver-targeted genetic diseases franchise is actively underway.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4611","symbol_name":"AI医疗","start_time":0,"source_url":"","article_id":"1114112458","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114112458","pubTimestamp":1768271438,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beam Therapeutics (BEAM.US) shares surged more than 20% on Monday, closing up 22.29% at $33.69. This significant increase followed the company's announcement detailing its ongoing commitment to...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4611":"AI医疗","BK4139":"生物科技","BK4556":"基因编辑","BK4007":"制药","BEAM":"Beam Therapeutics, Inc.","LENZ":"Therapeutics","BK4505":"高瓴资本持仓","BK4539":"次新股","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"基因疗法开发进展推动Beam Therapeutics(BEAM.US)股价飙升","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1,"BEAM":1},"content_text":"Beam Therapeutics (BEAM.US) shares surged more than 20% on Monday, closing up 22.29% at $33.69. This significant increase followed the company's announcement detailing its ongoing commitment to establishing a sustainable and predictable model for advancing precision genetic medicines. The company highlighted recent progress within its liver-targeted genetic diseases and hematology franchise programs, outlined its strategic priorities for 2026, and noted an extension of its anticipated cash runway. The company's cash, cash equivalents, and marketable securities were valued at approximately $1.25 billion as of the end of 2025. The expected cash runway has been extended into 2029, which is projected to provide substantial support for the anticipated launch of risto-cel and the execution of the BEAM-302 pivotal development program. Furthermore, the expansion of the company's liver-targeted genetic diseases franchise is actively underway.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1114112458","isCrawlerRequest":true}